scispace - formally typeset
G

Giuseppe Paolisso

Researcher at Seconda Università degli Studi di Napoli

Publications -  518
Citations -  36557

Giuseppe Paolisso is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Insulin & Diabetes mellitus. The author has an hindex of 85, co-authored 479 publications receiving 33028 citations. Previous affiliations of Giuseppe Paolisso include National Institutes of Health & University of Udine.

Papers
More filters
Journal ArticleDOI

New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk

Josée Dupuis, +339 more
- 01 Feb 2010 - 
TL;DR: It is demonstrated that genetic studies of glycemic traits can identify type 2 diabetes risk loci, as well as loci containing gene variants that are associated with a modest elevation in glucose levels but are not associated with overt diabetes.
Journal ArticleDOI

Oxidative Stress and Diabetic Vascular Complications

TL;DR: The suggestion that the different susceptibility of diabetic patients to microvascular and macrovascular complications may be a function of the endogenous antioxidant status is suggested.
Journal ArticleDOI

A genome-wide association search for type 2 diabetes genes in African Americans.

Nichole D. Palmer, +384 more
- 04 Jan 2012 - 
TL;DR: It is suggested that multiple loci underlie T2DM susceptibility in the African-American population and that these loci are distinct from those identified in other ethnic populations.
Journal Article

New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk (vol 42, pg 105, 2010)

Josée Dupuis, +303 more
- 01 May 2010 - 
Journal ArticleDOI

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, +798 more
- 27 Oct 2018 - 
TL;DR: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events, and evidence-based glucagon-like peptide 1 receptor agonists should be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events.